Gilead has partnered with Cognizant for more than three years now to adopt technologies designed to run business operations, new product la...

Today, a generation of expensive Gilead drugs containing the new iteration of tenofovir account for half of the market for HIV treatment an...

The researchers collected 374 blood samples -- two draws per patient during the first week after being diagnosed with SARS-CoV-2 infection ...

A voluntary licence (VL) is an authorisation given by the patent holder to a generic company to produce a patented drug while a compulsory ...

The company, which has development programs for conditions including hepatitis B, prostate cancer and non-small cell lung cancer, has raise...

A wide range of symptoms and severity makes the evaluation of Covid-19 vaccines tricky. The U.S. Food and Drug Administration has said that...

Drug patents in India are an important issue as many countries depend on generic drugmakers to make and sell cheaper versions of critical d...

This outperformance came after an underperformance of four years.

The U.S. Food and Drug Administration on Wednesday approved a radical new one-time treatment from the Swiss drugmaker, weeks earlier than e...

Biologics, also called biopharmaceuticals, have revolutionised treatment in chronic and serious illnesse and nudged traditional drugs out o...

It may be too early to forecast how Glenmark’s drugs will fare, for the next few years, the generics business will continue to be key.

In 2012, the company secured India's first compulsory licence to launch the generic version of Nexavar, Bayer's drug for treating liver and...

The government may negotiate prices of patented medicines with their manufacturers before allowing pharmaceutical companies to launch them ...

Every country’s patent laws are need-based to that country. That’s what I am trying to fight, and nobody is listening, Hamied said.

The biggest debate on price cuts is happening in the US with patients, insurers and the government joining in.

Drug companies say that they are not objecting to the control of healthcare costs, but it is the high-handed approach that is harming the i...

The recent Supreme Court judgement against Novartis has reopened old debates on drug patents, affordable healthcare and India as a destinat...